Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TN-101
- Development stage
- Preclinical
- Lead developer
- Tenaya Therapeutics
- Modality
- Gene Addition/Replacement → Gene Therapies, Gene Editing → Gene Therapies, Gene Silencing → Gene Therapies
- Administration
- Percutaneous
01
Overview
TN-101 is an investigational, preclinical-stage regenerative gene therapy being developed by Tenaya Therapeutics for the treatment of post-myocardial infarction (post-MI) heart failure. The therapy is designed to deliver cardiac reprogramming factors directly to resident cardiac fibroblasts in the heart, converting them into functional, beating cardiomyocytes (working myocardial cells) to restore heart function and reduce fibrotic scarring. Unlike systemic gene therapies, TN-101 is designed for localized, precise delivery directly into the heart tissue around the left ventricular scar area, typically utilizing an injection-based catheter approach to maximize therapeutic index and minimize systemic exposure.
- Other names
- Cardiac Reprogramming Gene TherapyCellular regenerationReprogramming
Beyond the preview
Go deeper on TN-101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TN-101.